1,077
Views
8
CrossRef citations to date
0
Altmetric
COMMENTARY

Medical Cannabis and Chronic Opioid Therapy

Pages 356-361 | Received 26 Aug 2010, Accepted 06 Sep 2010, Published online: 06 Dec 2010

REFERENCES

  • Frosch D. V.A. easing rules for users of medical marijuana. New York Times. July 23, 2010. Available at: http://www.nytimes.com/2010/07/24/health/policy/24veterans.html?_r=1&scp=1&sq=V.A.%20easing%20rules%20for%20users%20of%20medical%20marijuana&st=cse . Accessed August 16, 2010.
  • Ellis RJ, Toperoff W, Vaida F, Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–680.
  • Wilsey B, Marcotte T, Tsodikov A, A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–521.
  • Abrams DI, Jay CA, Shade SB, Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–521.
  • Wallace M, Schulteis G, Atkinson JH, Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007;107:785–796.
  • Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:1383–1391.
  • Gold MS, Roytberg A, Frost-Pineda K, Jacobs WS, Teitelbaum SA. Marijuana. In: Gabbard GO, ed. Treatment of Psychiatric Disorders. 4th ed. Arlington VA: American Psychiatric Publishing; 2006.
  • Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:849–863.
  • 2007 National Roadside Survey of Alcohol and Drug Use by Drivers. Drug results. Available at: http://www.nhtsa.org/DOT/NHTSA/Traffic%20Injury%20Control/Articles/Associ-ated%20Files/811249.pdf . Accessed August 11, 2010.
  • National Drug Intelligence Center. Domestic cannabis cultivation assessment 2009. National cannabis cultivation trends. July 2009. Available at http://www.justice.gov/ndic/pubs37/37035/national.htm#Figure1 . Accessed August 16, 2010.
  • Mehmedic Z, Chandra S, Slade D, Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55:1209–1217.
  • Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–360.
  • Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62:2098–2100.
  • Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102:211–216.
  • Ogborne AC, Smart RG, Weber T, Birchmore-Timney C. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs. 2000;32:435–443.
  • Goullé JP, Verstraete A, Boulu R, Costentin J, Foucher JP, Raes E, Tillement JP. [Illicit drugs, medications and traffic accidents]. Ann Pharm Fr. 2008;66:196–205.
  • Davey J, Leal N, Freeman J. Screening for drugs in oral fluid: illicit drug use and drug driving in a sample of Queensland motorists. Drug Alcohol Rev. 2007;26:301–307.
  • Terry P, Wright KA. Self-reported driving behaviour and attitudes towards driving under the influence of cannabis among three different user groups in England. Addict Behav. 2005;30:619–626.
  • Beirness DJ, Beasley EE. A roadside survey of alcohol and drug use among drivers in British Columbia. Traffic Inj Prev. 2010;11:215–221.
  • Walsh GW, Mann RE. On the high road: driving under the influence of cannabis in Ontario. Can J Public Health. 1999;90:260–263.
  • Berghaus G, Scheer N, Schmit P. Effects of cannabis on psychomotor skills and driving performance—a metaanalysis of experimental studies. 13th International Conference on Alcohol, Drugs and Traffic Safety (T'95). Available at: http://casr.adelaide.edu.au/T95/paper/s16p2.html . Accessed July 28, 2010.
  • Leirer VO, Yesavage JA, Morrow DG. Marijuana carry over effect on aircraft pilot performance. Aviat Space Environ Med 1991;62:221–227.
  • Hunault CC, Mensinga TT, Böcker KB, Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl). 2009;204:85–94.
  • Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23:266–277.
  • Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 2004;73:109–119.
  • Khiabani HZ, Bramness JG, Bjorneboe A, Morland J. Relationship between THC concentration in blood and impairment in apprehended drivers. Traffic Inj Prev. 2006;7:111–116.
  • Drummer OH, Gerostamoulos J, Batziris H, The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int. 2003;134:154–162.
  • Biecheler MB, Peytavin JF, Facy F, Martineau H. SAM survey on “drugs and fatal accidents”: search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. Traffic Inj Prevent. 2008;9:11–21.
  • Bédard M, Dubois S, Weaver B. The impact of cannabis on driving. Can J Public Health. 2007;98:6–11.
  • Mann RE, Stoduto G, Ialomiteanu A, Asbridge M, Smart RG, Wickens CM. Self-reported collision risk associated with cannabis use and driving after cannabis use among Ontario adults. Traffic Inj Prevent. 2010;11:115–122.
  • Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25:559–577.
  • Chou R, Fanciullo GJ, Fine PG, for the American Pain Society–American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.
  • Dupont RL, Talpins SK. Drugged driving and prescription drug use. Institute for Behavior and Health. Available at: http://www.ibhinc.org/pdfs/DDCommentaryonDruggedDriv-ingPrescriptionDrugs3910.pdf . Accessed August 17, 2010.
  • Breivik H. Stable long-term opioid medication per se does not always cause loss of driving ability: the doctor and patient must consider additional risk factors for unsafe driving. Acta Anaesthesiol Scand. 2006;50:651–6522.
  • Kress HG, Kraft B. Opioid medication and driving ability. Eur J Pain. 2005;9:141–144.
  • Dubois S, Bedard M, Weaver B. The association between opioid analgesics and unsafe driving actions preceding fatal crashes. Accid Anal Prev. 2010;42:30–37.
  • Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17:597–602.
  • Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared to alcohol on driving. Am J Addict. 2009;18:185–193.
  • Biecheler MB, Peytavin JF, Facy F, Martineau H. SAM survey on “drugs and fatal accidents”: search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. Traffic Inj Prev. 2008;9:11–21.
  • Cone EJ, Caplan YH, Black, DL, Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32:530–543.
  • Crancer A, Crancer A. The involvement of marijuana in California fatal motor vehicle crashes 1998–2008. Institute for Behavior and Health, Inc working paper. Available at: http://druggeddriving.org/pdfs/CAMJStudyJune2010.pdf . Accessed July 27, 2010.
  • Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: results from a national US survey. Addiction. 2008;103:258–268.
  • Blazer DG, Wu LT. Nonprescription use of pain relievers by middle-aged and elderly community-living adults: National Survey on Drug Use and Health. J Am Geriatr Soc. 2009;57:1252–1257.
  • Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 2009;10:1434–1441.
  • Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci. 2001;21:823–833.
  • Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276:2048–2050.
  • Collier DA. The genetics of cannabis involvement in humans: a genetic perspective. Addiction. 2006;101:780–781.
  • Ellgren M, Spano SM, Hurd YL. Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology. 2007;32:607–615.
  • Pesce A, West C, Rosenthal M, Marijuana correlates with use of other drugs in a pain patient population. Pain Physician. 2010;13:283–287.
  • Marijuana & Money: a CNBC special report. A galley of medical marijuana. Available at: http://www.cnbc.com/id/28561896?slide=6 . Accessed August 17, 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.